Standardized report for prostate biopsies;Fiche compte rendu standardisé et biopsies prostatiques

Annales de Pathologie

Volumn 28, Issue 5, 2008, Pages 459-466

  Molinié, Vincent ^a   Sibony, Mathilde ^b   Fromont, Gaëlle ^c   de Fromont, Marc ^d   Aillet, Geneviève ^e   Balaton, André ^a,f   Aymard, Bernadette ^g   Peneau, Michel ^h   Soulié, Michel ⁱ  

^a SAINT JOSEPH HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d Laboratoire d'anatomie pathologique et cytologie   (France)

^e Institut histopathologie   (France)

^f Centre de Pathologie   (France)

^g Centre de Pathologie   (France)

^h CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY; CLASSIFICATION; HUMAN; MALE; MEDICAL RECORD; PATHOLOGY; PROSTATE DISEASE; PROSTATE TUMOR; STANDARD;

BIOPSY; HUMANS; MALE; MEDICAL RECORDS; PATHOLOGY; PROSTATIC DISEASES; PROSTATIC NEOPLASMS;

EID: 58849130173     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2008.06.034     Document Type: Article

References (34)

1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008;53(1):68-80.
2. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005:20-33.
3. Boccon-Gibod L, van der Kwast TH, Montironi R, Boccon-Gibod L, Bono A. Handling and pathology reporting of prostate biopsies. Eur Urol 2004;46:177-81.
4. Soulié M, Barré C, Beuzedoc P, Chautard D, Cornud F, Eschwege P, et al. Cancer de prostate. Prog Urol 2004;14:913, 915-955.
5. Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond ME. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000;124:1034-9.
6. Villers A, Pommier P, Bataillard A, Fervers B, Bachaud JM, Berger N, et al. Summary of the standards, options and recommendations for the management of patients with nonmetastatic prostate cancer (2001). Br J Cancer 2003;89(Suppl 1):S50-8.
7. Molinié V, Vieillefond A, Cochand-Priollet B, Dauge-Geffroy MC, Lefrère-Belda MA, de Fromont M, et al. Recommandations pratiques pour les prélèvements prostatiques. Ann Pathol 1999;19:549-56.
8. Denoux Y, Blanc-Vincent MP, Simony-Lafontaine J, Verriele-Beurrier V, Briffod M, Voigt JJ. Standards, options et recommandations 2002 bonnes pratiques de l'acheminement et de la prise en charge initiale d'un prélèvement en anatomie et cytologie pathologiques en cancérologie. Ann Pathol 2003;23:266-78.
9. Rubin MA, Allory Y, Molinié V, Leroy X, Faucon H, Vacherot F, et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005;66:930-4.
10. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol 2000;114:896-909.
11. Che M, Sakr W, Grignon D. Pathologic features the urologist should expect on a prostate biopsy. Urol Oncol 2003;21:153-61.
12. Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 2005;18:886-90.
13. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000;124:98-107.
14. Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J, et al. Needle core length in sextant biopsy influences prostate cancer detection rate. Urology 2002;59:698-703.
15. Molinié V. Foyer minime, foyer suspect et néoplasies intraépithéliales prostatiques de haut grade. Quelles significations ? Quelles consequences ? Prog Urol 2004;14:2-6.
16. Ruffion A, Villers A, Molinie V. Prise en charge en cas de lésions précancéreuses de prostate isolées (HG-PIN) découvertes sur des biopsies. Prog Urol 2003;13:1268-71.
17. Villers A, Molinie V. Indication et stratégie de nouvelles biopsies après diagnostic de néoplasie intra-épithéliale prostatique. Prog Urol 2000;10:1267-70.
18. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004;17:307-15.
19. Fine SW, Epstein JI. Minute foci of Gleason score 8-10 on prostatic needle biopsy: a morphologic analysis. Am J Surg Pathol 2005;29:962-8.
20. Lewis Jr JS, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 2002;118:442-50.
21. Bismar TA, Lewis Jr JS, Vollmer RT, Humphrey PA. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003;27: 432-40.
22. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol 2000;18:2862-8.
23. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
24. Winkler MH, Khan FA, Kulinskaya E, Hoh IM, McDonald D, Boustead G, et al. The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy. BJU Int 2004;94:812-5.
25. Winkler MH, Kulinskaya E, Gillatt DA. Prediction of prostate cancer in extended-field biopsies of the prostate. BJU Int 2004;93:516-21.
26. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti Jr JC, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003;61:742-7.
27. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 2003;169:2136-41.
28. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti Jr JC, et al. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2003;98:2344-50.
29. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29: 1228-42.
30. De la Taille A, Viellefond A, Berger N, Boucher E, De Fromont M, Fondimare A, et al. Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. Hum Pathol 2003;34:444-9.
31. Molinié V. Néoplasie intra-épithéliale (PIN) prostatique. Diagnostic et conduite à tenir. Ann Pathol 2001;21: 245-54.
32. Molinié V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, et al. Diagnostic utility of a p63/alphamethyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol 2004;17:1180-90.
33. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-79.
34. Rubin MA, Dunn R, Kambham N, Misick CP, O'Toole KM. Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy ? Am J Surg Pathol 2000;24:1634-40.